Affimed NV (LTS:0HL9)
$ 2.22 0.1082 (4.73%) Market Cap: 38.03 Mil Enterprise Value: 25.31 Mil PE Ratio: 0 PB Ratio: 1.99 GF Score: 26/100

Q2 2019 Affimed NV Earnings Call Transcript

Aug 07, 2019 / 12:30PM GMT
Release Date Price: $29.4
Operator

Good day and welcome to Affimed's Second Quarter 2019 Financial Results and Corporate Update Conference Call.

(Operator Instructions) As a reminder, today's conference is being [recorded].

I'll now introduce your host for today's conference, Greg Gin, Head of Investor Relations at Affimed. Please go ahead, sir.

Gregory Gin
Affimed N.V. - Head of IR

Thank you, Maria. Thank you for joining us for Affimed's conference call to discuss the company's second quarter 2019 financial results and operational progress.

This morning, Affimed issued a press release, which is posted on the company's website at www.affimed.com.

On the call today are Adi Hoess, Chief Executive Officer of Affimed; Leila Alland, Chief Medical Officer; and Michael Wolf, Head of Finance, substituting for Florian Fischer today. We will begin today's call with opening remarks from Adi on our progress during the quarter. Leila will provide updates on the development program, and then Mike will

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot